News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Heather McKenzie and Nadia Bey
FDA
FDA Greenlights BMS, J&J CAR-T Therapies for Earlier Multiple Myeloma Treatment
The approvals, third line for BMS and 2seventy Bio’s Abecma and second line for J&J and Legend Biotech’s Carvykti, represent a new class of therapy for these blood cancer patients.
April 5, 2024
·
3 min read
·
Heather McKenzie and Nadia Bey
